Breast Cancer
Combined Clinical Staff Conference at the National Institutes of Health
- NATHANIEL I. BERLIN, M.D.;
- HOWARD B. ANDERVONT, D.SC. Bethesda, Maryland ;
- MICHAEL B. SHIMKIN, M.D. Philadelphia, Pennsylvania ;
- B. J. KENNEDY, M.D. Minneapolis, Minnesota ; and
- EMIL FREI III, M.D. Bethesda, Maryland
- Requests for reprints should be addressed to Nathaniel I. Berlin, M.D., Clinical Director, National Cancer Institute, Bldg. 10, Room 4-B-17 National Institutes of Health, Bethesda, Md. 20014.
Excerpt
Dr. Nathaniel I. Berlin: This Combined Clinical Staff Conference will be devoted to certain aspects of cancer of the breast. This is the most common malignant tumor in the female. It has been the subject of extensive study by surgeons, radiologists, endocrinologists, internists, and pathologists, and in the laboratory by studies in the mouse.
There has been a long-standing campaign, particularly sparked by the American Cancer Society, for self-examination with a view towards early detection. The National Cancer Institute is sponsoring a large-scale program to evaluate mammography in the subscribers to the Health Insurance Plan in New York City.
While
This 100-word excerpt has been provided in the absence of an abstract.
Summario in Interlingua
Carcinoma mammari es le tumor le plus commun in feminas. Le incidentia varia significativemente in differente partes del mundo. In le Statos Unite, nulle evidentia existe in supporto del these que in le curso del passate 20 o 30 annos ulle significative progresso ha essite obtenite in le effortio de prolongar le vita de tal patientes.
Un virus (agente de Bittner, virus de tumor mammari) ha essite identificate in le tumor mammari murin, e su rolo ha essite extensemente studiate.
Le tractamento initial de cancere mammari es, a generalmente parlar, chirurgia. Le extension de chirurgia a recommendar e le uso de radiotherapia ante o post le intervention chirurgic remane controverse. Therapias endocrine—tanto le excision de ovarios o del glandulas adrenal o pituitari como etiam le additive uso therapeutic de estrogenos, androgenos, o corticoides—ha essite studiate extensemente, e regulas standard pro su utilisation es summarisate. Le uso chimotherapeutic de altere agentes es relativemente recente e le rolo possibilemente alternative de tal agentes remane a determinar.
Article and Author Information
-
This is an edited transcription of a combined clinical staff conference at the Clinical Center, Bethesda, Md., by the National Cancer Institute, National Institutes of Health, Public Health Service, United States Department of Health, Education, and Welfare.
-
- Received May 5, 1965.
- Accepted May 11, 1965.
Most Read
